BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/10/24
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)GlobeNewsWire • 04/07/24
BridgeBio Pharma: Assessing Acoramidis' Market Opportunity, Further Upside Potential EvidentSeeking Alpha • 03/22/24
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?Investors Business Daily • 03/04/24
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CMGlobeNewsWire • 03/04/24
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateGlobeNewsWire • 02/22/24
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 02/15/24
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in JapanGlobeNewsWire • 02/07/24
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)GlobeNewsWire • 02/05/24
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 MonthsGlobeNewsWire • 02/02/24
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease TherapeuticsPRNewsWire • 01/30/24
BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic MedicinesGlobeNewsWire • 01/18/24
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of MedicineGlobeNewsWire • 01/10/24
BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)GlobeNewsWire • 01/03/24
BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with AchondroplasiaGlobeNewsWire • 12/13/23